Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$7.61 USD
+0.11 (1.47%)
Updated Apr 22, 2024 11:53 AM ET
After-Market: $7.57 -0.04 (-0.53%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Voyager Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 132.33 | -46.41 | -71.20 | 36.74 | -43.60 |
Depreciation/Amortization & Depletion | 0.82 | 6.18 | 5.51 | 3.84 | -0.82 |
Net Change from Assets/Liabilities | -66.56 | 20.47 | 3.29 | -144.54 | 78.44 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.33 | 7.25 | 8.86 | 7.24 | 14.64 |
Net Cash From Operating Activities | 77.92 | -12.51 | -53.53 | -96.72 | 48.67 |
Property & Equipment | -3.26 | -2.49 | -1.61 | -12.10 | -7.55 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -138.39 | -4.85 | 67.52 | 125.09 | -82.93 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -141.64 | -7.34 | 65.91 | 113.00 | -90.48 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 33.65 | 1.11 | 0.61 | 3.16 | 80.99 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 33.65 | 1.11 | 0.61 | 3.16 | 80.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -30.08 | -18.74 | 12.99 | 19.44 | 39.18 |
Cash at Beginning of Period | 100.47 | 119.21 | 106.22 | 86.78 | 47.59 |
Cash at End of Period | 70.40 | 100.47 | 119.21 | 106.22 | 86.78 |
Diluted Net EPS | 2.97 | -1.21 | -1.89 | 0.98 | -1.21 |
Fiscal Year End for Voyager Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 132.33 | 75.94 | 101.84 | 124.04 |
Depreciation/Amortization & Depletion | NA | 0.82 | 1.27 | 2.14 | 1.06 |
Net Change from Assets/Liabilities | NA | -66.56 | 16.22 | 13.40 | -4.14 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 11.33 | 8.25 | 5.35 | 2.60 |
Net Cash From Operating Activities | NA | 77.92 | 101.68 | 122.73 | 123.57 |
Property & Equipment | NA | -3.26 | -2.50 | -1.72 | -0.51 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -138.39 | -165.98 | -8.45 | 15.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -141.64 | -168.48 | -10.17 | 14.49 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 33.65 | 33.19 | 32.85 | 31.31 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 33.65 | 33.19 | 32.85 | 31.31 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -30.08 | -33.61 | 145.41 | 169.36 |
Cash at Beginning of Period | NA | 100.47 | 100.47 | 100.47 | 100.47 |
Cash at End of Period | NA | 70.40 | 66.86 | 245.89 | 269.84 |
Diluted Net EPS | NA | 1.13 | -0.59 | -0.51 | 2.94 |